

**RESOLUTIONS PASSED AT THE ANNUAL GENERAL MEETING HELD ON 27 SEPTEMBER 2022**

*Capitalised terms used herein, unless otherwise defined, shall have the definitions ascribed to them in the annual report of the Company for the financial year ended 31 May 2022 (“AR2022”) and the appendix to the AR2022 which were despatched to shareholders of HC Surgical Specialists Limited (the “Company”) on 5 September 2022.*

The Board of Directors of the Company is pleased to announce that, pursuant to Rule 704(15) of the Singapore Exchange Securities Trading Limited (“SGX-ST”) Listing Manual Section B: Rules of Catalist (the “Catalist Rules”), all of the resolutions set out in the Notice of the Annual General Meeting (“AGM”) dated 5 September 2022 were duly passed by way of poll, at the AGM held on 27 September 2022, by way of electronic means.

(a) The results of the poll on the resolutions put to the vote at the AGM are as follows:

Resolution number and details	Total number of shares represented by votes for and against the relevant resolution	For		Against		
		Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	
<b>Ordinary Business</b>						
1	Re-election of Dr. Heah Sieu Min as Director of the Company <sup>(1)</sup>	107,678,575	107,678,575	100.00	0	0.00
2	Re-election of Mr. Lim Chye Lai, Gjan as Director of the Company <sup>(2)</sup>	107,458,575	107,458,575	100.00	0	0.00
3	Directors’ Fees of S\$111,000/- for the financial year ended 31 May 2022	107,678,575	107,678,575	100.00	0	0.00
4	Declaration of final dividend (tax-exempt one-tier) of S\$0.012 per ordinary share for the financial year ended 31 May 2022	107,678,575	107,678,575	100.00	0	0.00

Resolution number and details		Total number of shares represented by votes for and against the relevant resolution	For		Against	
			Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
<b>Ordinary Business</b>						
5	Re-appointment of Messrs BDO LLP as auditors of the Company	107,678,575	107,230,575	99.58%	448,000	0.42%
<b>Special Business</b>						
6	Authority to issue ordinary shares	107,678,575	107,678,575	100.00	0	0.00
7	Authority to issue shares under the HCSS Performance Share Plan	107,678,575	107,678,575	100.00	0	0.00
8	Authority to issue shares under the HCSS Employee Share Option Scheme	107,678,575	107,678,575	100.00	0	0.00
9	Proposed Renewal of the Share Buy-Back Mandate	43,689,595	43,689,595	100.00	0	0.00

**Notes:**

- (1) Dr. Heah Sieu Min, who was re-elected as a Director under Resolution 1, remains as the Executive Director and Chief Executive Officer of the Company.
- (2) Mr. Lim Chye Lai, Gjan, who was re-elected as a Director under Resolution 2, remains as the Non-Independent Non-executive Director and member of the Audit Committee, Nominating Committee and Remuneration Committee of the Company.
- (b) Details of the party who had abstained from voting on Resolution 9 and his shareholdings is as follows:

<u>Name</u>	<u>Number of shares held</u>
1. Dr. Heah Sieu Min	63,988,980

(c) Name of firm appointed as Scrutineer:

Entrust Advisory Pte. Ltd. was appointed as the scrutineer for the AGM.

By Order of the Board

Dr. Heah Sieu Min  
Executive Director and Chief Executive Officer

Date: 27 September 2022

---

### **About HC Surgical Specialists Limited**

HC Surgical Specialists Limited (the “Company”) was incorporated on 1 September 2015 in Singapore and listed on the Catalist of the Singapore Exchange Securities Trading Limited on 3 November 2016. The Company, its subsidiaries and associated company are a medical services group primarily engaged in the provision of endoscopic procedures, including gastroscopies and colonoscopies, and general surgery services with a focus on colorectal procedures across a network of 16 clinics located throughout Singapore.

---

This announcement has been prepared by the Company and reviewed by the Company’s sponsor, Novus Corporate Finance Pte. Ltd. (the “Sponsor”), in compliance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #18-03B Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.